bioAffinity Technologies Launches Veteran Lung Health Program with Philips and 4DMedical
Key Points from the Report
- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) is spearheading an initiative to improve lung health screening among U.S. veterans, a population at elevated risk for lung cancer and other respiratory diseases.
- The program features a July 21, 2026, educational webinar hosted by the National Association of Veterans’ Research and Education Foundations (NAVREF), bringing together clinical experts to discuss state-of-the-art approaches in early lung disease detection.
- The webinar will cover mobile CT screening, CyPath® Lung noninvasive testing, and advanced functional lung imaging to improve early detection, reduce costs, and increase access for veterans.
- Panelists include top medical professionals from Philips, 4DMedical, and RWJBarnabas Health, offering deep insight into both clinical implementation and innovation in lung diagnostics.
- CyPath® Lung, bioAffinity’s flagship test, demonstrated compelling results in a clinical trial: 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value (NPV) for early-stage lung cancer detection in high-risk patients with small lung nodules.
- CyPath® Lung is marketed as a Laboratory Developed Test (LDT) and is not intended to be used as the sole diagnostic but as part of a comprehensive clinical assessment.
- The initiative aligns with the recent PACT Act, which recognizes toxic exposures among veterans and raises awareness for the necessity of early screening programs in this population.
Details and Potential Shareholder Impact
bioAffinity Technologies’ latest announcement signals a strategic push into the veterans’ healthcare market, a significant and underserved segment with higher-than-average rates of lung cancer. By partnering with Philips and 4DMedical, two reputable names in medical technology and imaging, bioAffinity is reinforcing its position as an innovator in noninvasive cancer diagnostics.
The upcoming educational webinar, scheduled for July 21, 2026 (6 p.m. ET/5 p.m. CT), is poised to showcase real-world case studies and the integration of novel diagnostic tools. Key discussion topics will include:
- The elevated risk of lung cancer among veterans and the critical need for early detection.
- The expanding role of advanced imaging and noninvasive diagnostics, such as CyPath® Lung and 4DMedical’s proprietary lung imaging platform, in clinical care.
- Strategies to improve access to screening and follow-up care for veterans, especially in the wake of toxic exposures recognized under the PACT Act.
- Implementation considerations for comprehensive lung health programs involving public, private, and nonprofit stakeholders.
Featured speakers include:
- Rashi Romanoff (NAVREF CEO, moderator), facilitating public-private partnerships for veteran health innovation.
- Dr. Amy Rohs (Philips), a leader in tele-critical care and healthcare innovation, with VA and military medicine expertise.
- Dr. Michael Nicholson (RWJBarnabas Health), a pulmonary and critical care specialist with experience in noninvasive malignancy risk stratification using CyPath® Lung.
- Dr. Greg Mogel (4DMedical CMO), a veteran and radiologist with a track record of establishing large-scale lung cancer screening programs.
CyPath® Lung: Market and Clinical Advantages
CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to analyze sputum samples, identifying cellular markers of malignancy. The test incorporates a fluorescent porphyrin preferentially taken up by cancerous and cancer-related cells.
The test’s high negative predictive value (99%) suggests that a negative result gives physicians high confidence to rule out malignancy, potentially reducing unnecessary invasive procedures and associated healthcare costs.
CyPath® Lung is currently marketed as an LDT by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, and is regulated under CLIA guidelines. While not intended as a standalone diagnostic, it is positioned as a valuable adjunct to existing diagnostic pathways for high-risk patients.
Shareholder Considerations and Price-sensitive Information
- Entry into the Veterans’ Healthcare Market: By targeting veterans, bioAffinity is expanding its addressable market, potentially increasing test adoption and revenue. The collaboration with Philips and 4DMedical could lead to further commercial and research opportunities.
- Positive Clinical Data: The strong performance metrics for CyPath® Lung (sensitivity, specificity, and NPV) may increase physician confidence and accelerate market uptake, positively influencing sales growth and share value.
- Strategic Partnerships: The involvement of leading organizations (Philips, 4DMedical, NAVREF) enhances credibility and could drive broader healthcare system adoption, creating potential for additional revenue streams and long-term growth.
- Regulatory and Commercial Risks: Shareholders should be aware that CyPath® Lung is an LDT, and changes in regulatory oversight could impact marketability. The company states that forward-looking statements are subject to risks, including the ability to commercialize CyPath® Lung and changes in the regulatory environment for LDTs.
- Upcoming Events: The July 21 webinar could serve as a catalyst for increased industry and investor attention, especially if new data, partnerships, or commercial milestones are announced.
Conclusion
The announcement reflects bioAffinity Technologies’ ambition to lead in the early detection of lung cancer, particularly within high-risk populations such as veterans. The company’s focus on innovative, noninvasive diagnostics, strategic partnerships, and validated clinical performance metrics position it for potential growth. Investors should monitor the outcomes of the July 21 webinar and subsequent commercial developments, as these could materially impact share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information is based on company disclosures and may be subject to risks, uncertainties, and changes in the business or regulatory environment.
